#Tavapadon
LightNews LightNews
global-news-2024.bsky.social
🤖 New drug for Parkinson’s shown to be effective in clinical trials: 'Very encouraged'
Key points:
• In patients taking at least 400 mg of levodopa daily, tavapadon helped reduce motor fluctuations....
#Drug #Tavapadon #Parkinson
Source: Fox News | What are your thoughts?
April 18, 2025 at 9:31 AM
newsen.bsky.social
AbbVie's Tavapadon Shows Promising Results in Phase 3 Parkinson's Disease Trial#USA#Parkinson's#AbbVie#North_Chicago#Tavapadon
AbbVie's Tavapadon Shows Promising Results in Phase 3 Parkinson's Disease Trial
AbbVie reveals encouraging outcomes for Tavapadon in its Phase 3 TEMPO-2 trial, potentially offering new hope for Parkinson's Disease treatment.
third-news.com
December 9, 2024 at 1:08 PM
michaelbani.bsky.social
AbbVie’s Tavapadon shows huge potential for Parkinson’s patients in early stages. A hopeful step in treating this challenging condition.
#Parkinsons #BrainHealth #Neurology #ParkinsonsDisease #HealthNews #MedicalBreakthrough #ScienceUpdates #NewMedicines #ClinicalTrials #DiseaseAwareness
December 11, 2024 at 12:46 AM
news-feed.bsky.social
@Forbes: Parkinson’s Disease Drug Tavapadon Significantly Improved Symptom Control, Cerevel Says
https://t.co/AWP2E88Zp7 https://t.co/sNWUKDxedL
April 18, 2024 at 2:41 PM
kstrategyand.bsky.social
www.linkedin.com/pulse/abbvie...

AbbVie’s Tavapadon Shines in Phase 3 Trials for Parkinson’s Disease

#ParkinsonsDisease #Tavapadon #AbbVie #NeurologicalDisorders #DopamineReceptors #Phase3Trials #ClinicalResearch #MotorSymptomRelief #Humanteconomy #Humantec
AbbVie’s Tavapadon Shines in Phase 3 Trials for Parkinson’s Disease
AbbVie’s investigational drug Tavapadon has achieved positive results in the Phase 3 TEMPO-2 trial, a critical milestone in developing new therapies for Parkinson’s disease. Designed as a flexible-dos...
www.linkedin.com
December 13, 2024 at 11:40 AM
fintwitter.bsky.social
ABBVIE FILES NEW DRUG APPLICATION WITH U.S. FDA FOR TAVAPADON TO TREAT PARKINSON'S DISEASE
September 26, 2025 at 12:46 PM
journosnews.com
Tavapadon: A Once-Daily Drug That Helps Parkinson’s Patients Without Side Effects
#ParkinsonsDisease #Tavapadon #ParkinsonsTreatment #MotorSymptoms #ClinicalTrials #NewDrug #ParkinsonsResearch #DopamineAgonist #ParkinsonsRelief #HealthBreakthrough #ParkinsonsCare #NeurodegenerativeDisease
New Parkinson’s Drug Tavapadon Shows Promise in Clinical Trials
New Parkinson’s Drug Tavapadon Offers Hope, Reducing Symptoms Without Side Effects A promising new drug, tavapadon, has shown significant potential
journosnews.com
April 18, 2025 at 2:49 PM
stocktitan.net
#ABBV AbbVie Submits New Drug Application to U.S. FDA for Tavapadon for the Treatment of Parkinson's Disease

https://www.stocktitan.net/news/ABBV/abb-vie-submits-new-drug-application-to-u-s-fda-for-tavapadon-for-29v4cv003eaf.html
Breakthrough Once-Daily Oral Treatment: AbbVie's Tavapadon Shows Significant Motor Control in Parkinson's Trials
AbbVie submits NDA for tavapadon following successful Phase 3 TEMPO trials showing improved motor function in Parkinson's patients. Once-daily oral treatment demonstrated efficacy across disease stages.
www.stocktitan.net
September 26, 2025 at 12:45 PM
amarsahay.bsky.social
Parkinson's Drug approval: Win for patients. AbbVie’s tavapadon “significantly” improved patients’ score versus placebo on a set of scales that measure motor function at 26 weeks, good for a p-value of <0.0001 in the trial’s primary endpoint.
endpts.com/abbvie-decla...
AbbVie declares third Phase 3 Parkinson’s win from Cerevel takeover
There’s a silver lining for AbbVie on its closely-followed buyout of Cerevel: The pharma company reported Monday that its Parkinson’s disease candidate notched another win.
endpts.com
December 9, 2024 at 4:59 PM
fintwitter.bsky.social
AbbVie Files Application with U.S. FDA for Tavapadon as New Parkinson's Disease Treatment 🧬💊
September 26, 2025 at 12:47 PM
amjeditor.bsky.social
In early Parkinson’s, tavapadon significantly reduced OFF time in the TEMPO-2 trial. Hopeful news for improving quality of life with a once-daily oral therapy. #AANAM
🔗 www.emjreviews.com/en-us/amj/ne...
Parkinson’s Symptoms Improved in TEMPO-2 Trial: AAN 2025
The Phase 3 TEMPO-2 trial presented at AAN 2025 reported that tavapadon significantly improved motor symptoms and daily function in adults with early Parkinson’s disease.
www.emjreviews.com
April 10, 2025 at 5:43 PM
fintwitter.bsky.social
ABBVIE FILES APPLICATION WITH U.S. FDA FOR TAVAPADON AS NEW PARKINSON'S DISEASE TREATMENT
September 26, 2025 at 12:46 PM
hlatim.bsky.social
From Wikipedia - Tavapdon MOA- Tavapadon acts as a highly selective partial agonist of the dopamine D1 receptor (Ki = 9 nM; IA Tooltip Intrinsic activity = 65%) and the dopamine D5 receptor (Ki = 13 nM; IA = 81%).
December 10, 2024 at 2:32 PM
todayheadline.bsky.social
Hope for Parkinson’s disease symptoms is found in late-stage drug study todayheadline

Tavapadon aims to treat Parkinson’s motor symptoms by mimicking dopamine in a once-a-day oral dose. Read More
Hope for Parkinson’s disease symptoms is found in late-stage drug study todayheadline
Tavapadon aims to treat Parkinson’s motor symptoms by mimicking dopamine in a once-a-day oral dose. Read More
todayheadline.co
December 10, 2024 at 5:42 PM
stocktitan.net
#ABBV AbbVie Announces Positive Topline Results for the Phase 3 TEMPO-2 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease

#stocks #StockMarket #investing

https://www.stocktitan.net/news/ABBV/abb-vie-announces-positive-topline-results-for-the-phase-3-tempo-2-64xx4n90m3k5.html
AbbVie's Parkinson's Drug Tavapadon Shows Breakthrough Results in Phase 3 Trial
AbbVie reports significant success in Phase 3 trial for early Parkinson's treatment, with tavapadon showing major improvements in motor function and daily living activities.
www.stocktitan.net
December 9, 2024 at 1:00 PM
scienceofpd.bsky.social
Abbvie announces that their once-daily drug, tavapadon, improves #Parkinsons patient mobility in late-stage study
www.reuters.com/business/hea...
AbbVie's Parkinson's disease drug improves patient mobility in late-stage study
AbbVie's experimental drug to treat early Parkinson's disease helped significantly improve patients' ability to carry out daily tasks such as eating and walking, months after the drugmaker disclosed its success in a separate study.
www.reuters.com
December 10, 2024 at 10:35 PM
rcatanho.bsky.social
Tavapadon, agonista parcial D1/D5, mejora la función motora y reduce los problemas de control del impulso y mareos en pacientes con Parkinson temprano firstwordpharma.com/story/5919666
FirstWord
firstwordpharma.com
December 10, 2024 at 7:11 AM
biobonanos.bsky.social
Tavapadon, acquired by AbbVie in its purchase of Cerevel, has met the primary endpoint in a Phase III study to treat Parkinson's disease www.prnewswire.com/news-release...
AbbVie Announces Positive Topline Results from Phase 3 TEMPO-1 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease
/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive topline results from its pivotal Phase 3 TEMPO-1 trial for tavapadon as a monotherapy in early...
www.prnewswire.com
September 26, 2024 at 12:09 PM
sbzmusic.bsky.social
New drug for Parkinson’s shown to be effective in clinical trials: ‘Very encouraged’

A new drug has shown promise in combating Parkinson’s disease while minimizing unwanted side effects. The once-daily pill, tavapadon, was found to relieve symptoms — including stiffness, coordination, tremors and…
New drug for Parkinson’s shown to be effective in clinical trials: ‘Very encouraged’
A new drug has shown promise in combating Parkinson’s disease while minimizing unwanted side effects. The once-daily pill, tavapadon, was found to relieve symptoms — including stiffness, coordination, tremors and movement — for a longer period of time for patients who were also taking at least 400 mg of levodopa a day and were […] New drug for Parkinson’s shown to be effective in clinical trials: ‘Very encouraged’
stayhealthyweekly.news
April 19, 2025 at 12:33 PM
opqwe0.bsky.social
Expectations for the symptoms of Parkinson’s disease are found in the study of delayed treatment

Tavapadon is intended to treat the motor symptoms of Parkinson's disease by taking a once-daily oral dose of dopamine. read more Source link
Expectations for the symptoms of Parkinson’s disease are found in the study of delayed treatment
Tavapadon is intended to treat the motor symptoms of Parkinson's disease by taking a once-daily oral dose of dopamine. read more Source link
mbcd.xyz
December 10, 2024 at 5:53 PM
sketchynews.net
[Parkinson's News Today]AAN 2025: Tavapadon offers rapid, sustained motor benefits - Parkinson's News Today Tavapadon eased motor symptoms in a month when given at either a fixed or flexible dose to adults with early-stage disease, data showed.
April 13, 2025 at 8:45 PM
geniousgrow.bsky.social
Hope for Parkinson’s disease symptoms is found in late-stage drug study

Tavapadon aims to treat Parkinson’s motor symptoms by mimicking dopamine in a once-a-day oral dose. Read More
Hope for Parkinson’s disease symptoms is found in late-stage drug study
Tavapadon aims to treat Parkinson’s motor symptoms by mimicking dopamine in a once-a-day oral dose. Read More
geniousgrow.online
December 10, 2024 at 5:12 PM
newsen.bsky.social
AbbVie Proposes New Treatment Tavapadon to Combat Parkinson's Disease in Latest FDA Application#United_States#Parkinsons#AbbVie#North_Chicago#Tavapadon
AbbVie Proposes New Treatment Tavapadon to Combat Parkinson's Disease in Latest FDA Application
AbbVie has submitted a New Drug Application for Tavapadon to treat Parkinson's Disease, showing promising results in Phase 3 trials and aiming for improved patient care.
third-news.com
September 26, 2025 at 12:57 PM
michaelokun.bsky.social
A newly designed more selective dopamine agonist drug for Parkinson's (Tavapadon) announced a positive phase 3 trial. Works on D1/D5 dopamine receptors, is a partial dopamine agonist, is long acting, and investigators hoping it is limited to direct 'motor basal ganglia pathway
November 25, 2024 at 1:35 PM